2023.09.05
I-Mab Announces Upcoming Participation at September Conferences
I-Mab announced participation in investor conferences in September 2023.
2023.08.17
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
The Company today announced its financial results for the 6 months ended June 30, 2023, and provided key business updates.
2023.08.08
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
I-Mab will host an investor call to report interim earnings on Aug 17.
2023.07.05
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC
The Company published a manuscript in JITC demonstrating mechanism of givastomig in the treatment of CLDN18.2-expressing tumors through the targeted activation of 4-1BB mediated T cells.
2023.06.22
I-Mab Announces the Appointment of Raj Kannan as CEO
Mr. Raj Kannan joins the Company as Chief Executive Officer and a member of the board of directors.
2023.05.26
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
The Company reports encouraging clinical results of uliledlimab at the ASCO Annual Meeting.
2023.04.26
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
The Company will present a poster featuring the latest clinical data of uliledlimab in combination with PD-1 therapy in NSCLC at ASCO 2023.
2023.04.25
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute.
2023.04.24
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
The first patient in a Phase 3 registrational trial in China for patients with HR-MDS has been dosed with lemzoparlimab in combination with AZA.
2023.03.31
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022
The Company today announced its financial results for the 12 months ended December 31, 2022, and provided key business updates.